Interim Report

January–March 2026

Key figures, Group

	Q1		Full year
	2026	2025	2025
Net sales (SEK thousand)	-	-	-
Loss before Income tax (SEK thousand)	-35,380	-42,321	-171,546
Earnings per share before dilution (SEK)	-0.85	-1.14	-4.46
Earnings per share after dilution (SEK)	-0.85	-1.14	-4.46
Research and development expenses as % of operating expenses*	6.5	11.8	6.6
Cash and cash equivalents (SEK thousand)	120,721	125,725	153,745
Total assets (SEK thousand)	736,388	737,708	769,346
Equity/assets ratio (%)	77.3	78.7	78.6
Average number of employees	24	26	26

*Definitions of key figures, p. 20

January–March 2026, Group

- Net sales amounted to SEK 0 thousand (0)
- Earnings before tax amounted to SEK -35,380 thousand (-42,321)
- Earnings per share before dilution amounted to SEK -0.85 (-1.14)
- Cash flow from operating activities amounted to SEK -30,676 thousand (-66,329)
- Cash flow from investing activities amounted to SEK -1,067 thousand (-14,701)

Amounts in parentheses refer to the year-earlier period.

Significant events during the quarter

- In February, Blake Leitch was appointed Chief Executive Officer, effective no later than June 1, 2026. He succeeds Per Andersson, who continues in the role of Chief Scientific Officer.
- In February, Xspray Pharma announced that it had re-submitted its application for market approval for Dasynoc® to the US Food and Drug Administration (FDA). The resubmission includes the additional information requested by the FDA.
- In March, the FDA announced that it had accepted the resubmitted application for market approval of Dasynoc® for review and set a PDUFA date of August 25, 2026, which is the date when the agency is expected to announce a decision on the application.
- In March, the company announced that the Board had resolved to carry out a new issue of shares for approximately SEK 83 million, with preferential rights for the company's existing shareholders, as well as an over-allotment issue. In light of the oversubscription, the company resolved to increase the over-allotment issue from SEK 20 million to SEK 30 million.

Significant events after the reporting period

- In April, Xspray Pharma announced that the FDA had accepted the proprietary name Nilopki® for the company's drug candidate XS003 (nilotinib), ahead of a planned launch in the US in the second half of 2026, subject to FDA approval.
- In April, Xspray Pharma announced the outcome of the Company's rights issue, which was significantly oversubscribed with subscriptions corresponding to approximately 258 percent of the offered shares. In light of the strong investor interest, the Board of Directors resolved to fully exercise the over-allotment issue. Through the rights issue and the over-allotment issue, the Company will receive total issue proceeds of approximately SEK 113 million before transaction costs.

A message from the CEO

Dear shareholders,

We took several important steps in the first quarter of 2026 toward our ultimate goal of obtaining market approval for our products and making them available for all of the patients who truly need them.

Physicians confirm that there is a real need in the market

During and after the quarter, we held in-depth conversations with hematologists in the US – both through Advisory Boards and at conferences such as NCODA Global Congress 2026. These conversations provided me with more than just crucial strategic input. They have further strengthened my conviction that what we have achieved during our nearly 20 years fulfills a highly significant clinical need in the market.

In our analysis of real clinical patient data – corresponding to more than 35,000 patient-years – we are seeing a clear pattern that physicians can understand but rarely see quantified. Patients often switch treatments at an early stage – in most cases due to side effects. One widespread and underestimated problem is co-medication with proton-pump inhibitors (PPIs). A large proportion of all CML patients treat stomach problems with PPIs while taking dasatinib – which drastically impairs the uptake of the crystalline drug. This is an everyday clinical problem that currently lacks a good solution. The reaction from physicians when we presented this data and demonstrated how Dasynoc® addresses this problem was clear and straightforward – not politely interested, but genuinely engaged. Having persuasive clinical data in an application is one thing. Hearing the physicians who will soon be prescribing the product say that their patients actually need this, is another.

Regulatory status – we are close

We enter the second quarter with optimism. Two products are very close to approval. The PDUFA date for Dasynoc® is set to August 25, 2026, and for Nilopki® (XS003 nilotinib) to June 18, 2026. Our manufacturing partner in Italy is expected to be inspection-ready during the first half of the year. If the FDA is able to complete the inspection before the PDUFA date, approval could come as early as June 18. If the inspection instead takes place after the PDUFA date, the FDA is likely to issue a CRL (Complete Response Letter) that relates solely to the inspection and not to the product itself.

As soon as the inspection is approved, Xspray will inform the FDA that no remaining obstacles to approval exist. Both paths are consistent with Xspray's plan to launch in the U.S. during the second half of 2026.

We are following the situation closely and are well prepared for a dual launch of Dasynoc® and Nilopki® in the autumn of 2026.

The HyNap platform is stronger than ever

Having two NDA applications under review at the same time, for two separate products based on the same technology platform, is something quite unique – especially for a company of our size. With every regulatory response we formulated, and every CMC question we answered, we have built up a knowledge base that is now clearing a shorter – and less costly – path for the next product candidates.

Financing

The completed preferential rights issue will secure the capital requirement up through launch and give us the resources needed to genuinely start up commercial operations with full force. Additional financing – for example, in the form of loan financing – may be needed to complete a successful double launch and achieve cash-flow positivity. Our cost structure is suitably adapted to keep running costs down, with launch-related investments being capitalized in line with future approvals.

Looking ahead

Now that the company is entering an eagerly awaited commercial phase, I would like to welcome Blake Leitch as our new CEO – the right person, at the right time. I, myself, am looking forward to focusing on the technology and the science, and to developing the next generation of improved PKI drugs in my role as Chief Scientific Officer.

In conclusion, I would like to say that leading an organization with so many competent and committed people has been a glorious journey. There is no doubt in my mind that, scientifically and technically, we have essentially done everything correctly. What we sometimes underestimated was the methodology. In breaking new ground, it is easy to assume that the business environment is keeping pace, that partners understand the implications of what we are doing, and that government authorities are sending the right expertise to audit us. This has not always been the case, and it has cost us time and money. We have every reason to believe that this phase is now behind us. The dialogue with the FDA has matured, the technology has been established and documented, and our take-aways from this journey will shorten the path to market for the next products. Now, it is a matter of transforming all this into successful commercialization and a strong pipeline, and I am genuinely looking forward to the next phase.

Thank you all for your confidence.

Per Andersson
CEO

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with a number of product candidates under clinical development, and which has applied for market approval of its product candidates Dasynoc® and Nilopki®. Xspray Pharma uses its innovative, patented HyNap™ technology to develop improved versions of protein kinase inhibitors (PKIs) for cancer treatments. PKIs are the largest drug group in the field of oncology, with just over 90 approved drugs in the US.

Vision

Xspray Pharma's vision is to use its patented HyNap technology to establish itself as a leading player for improved versions of marketed protein kinase inhibitors (PKIs) for cancer treatments, thereby increasing the quality of life and chances of survival for patients. Through a confirmed improvement profile and an active patent strategy, Xspray will capture market shares and create long-term profitability for the company and its owners.

Launch of Dasynoc® and Nilopki®

Xspray Pharma submitted an updated application for market approval of Dasynoc® in April 2025. In October 2025, the FDA issued a Complete Response Letter (CRL) regarding the company's application referring to GMP observations at a contract manufacturer. These observations did not concern Xspray Pharma's production line. The FDA also requested supplementary information to ensure that the proposed product information is appropriate. In February 2026, Xspray Pharma re-submitted an updated application that included the supplements requested by the FDA. The FDA has accepted the application for review and set a PDUFA date for August 25, 2026, which is FDA's deadline for responding with a decision regarding the application.

In August 2025, Xspray Pharma submitted an application for market approval for its product candidate Nilopki® for the treatment of chronic myeloid leukemia (CML) to the FDA. The application is based on successful studies demonstrating bioequivalence with the reference product Tasigna®. In October, the FDA announced that it had set a PDUFA date of June 18, 2026.

Xspray Pharma has a partnership agreement with EVERSANA that provides access to a cost-effective, ready-to-start sales organization for the entire US. EVERSANA stands ready to accelerate market preparations as final FDA approvals approach. EVERSANA will provide Xspray Pharma with services in market access, a medical sales organization, and patient support programs. EVERSANA has experts with extensive experience in selling PKI drugs to physicians, insurance companies, and other players that Xspray Pharma will be targeting. This will create good conditions for a rapid launch of Dasynoc® and Nilopki®. Xspray Pharma will retain full financial and strategic responsibility while EVERSANA will be engaged to assume responsibility for the launch of the two product candidates in the US. Xspray Pharma has conducted a number of market surveys in the US. These confirmed the company's view of the potential of Dasynoc®, and that the benefits of the product compared with competing PKI drugs are significant for physicians, nurses, and patients.

Market

Protein kinase inhibitors (PKIs) have become one of the most effective treatments of cancer and for certain types of cancer, PKIs are the only available option. PKIs are the largest drug class in the field of oncology, with over 3,000 ongoing clinical studies in Phase I, Phase II or Phase III, and just over 90 PKIs are approved treatments on the US market.

All Xspray Pharma's product candidates in development are currently PKIs. The rise in cancer and autoimmune diseases is an important factor that is expected to increase sales of PKIs.

Product candidates

Xspray Pharma's pipeline contains four announced product candidates. They are all based on the company's HyNap™ technology: Dasynoc®, Nilopki®, XS008 axitinib and XS025 cabozantinib. These product candidates are stable amorphous and non-crystalline versions of the four best-selling cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib), Inlyta® (axitinib) and Cabometyx® (cabozantinib). Many protein kinase inhibitors in the market are difficult to dissolve and often have a high degree of variability in uptake.

Xspray's amorphous formulation increases solubility, regardless of the pH of the stomach, which could lead to improved uptake and permit lower dosages to be administered to patients with retained efficacy. The total annual sales of the original drugs Sprycel®, Tasigna®, Inlyta® and Cabometyx® for 2024 exceeded USD 4.9 billion in the US market and USD 6.4 billion globally.[1]

Overview – product candidates

Product candidate				Patent		Development phase					
Project	Substance	Indication	Regulatory path	Substance patent expiry	Secondary patent expiry	New candidate evaluation	Development of formulation	Pilot studies	Pivotal studies	Regulatory review	Original product/Company
XS004	dasatinib	Leukemia (CML, ALL)	505(b)(2)	Dec 2020	Sep 2026						Sprycel®/ BMS
XS003	nilotinib	Leukemia (CML)	505(b)(2)	Jan 2024	Oct 2032						Tasigna®/ Novartis
XS008	axitinib	Renal cancer (RCC)	505(b)(2)	Apr 2025	Dec 2030						Inlyta®/ Pfizer
XS025	cabozantinib	Renal cancer (RCC)	505(b)(2)	Aug 2026	Jul 2033						Cabometyx®/ Exelixis

[1] The information regarding annual sales has been taken from the reference companies' quarterly reports and IPD analytics.

Share information

Xspray Pharma's share is listed on Nasdaq Stockholm under the symbol XSPRAY. The number of shares in the company at March 31, 2026 was 41,742,340 and the market price on that date was SEK 29.70.

Owners as of March 31, 2026	Number of shares	Share of capital & votes
Flerie Invest AB	7,336,187	17.57%
Anders Bladh (private & Ribbskottet)	5,061,842	12.13%
The Foundation for Baltic and East European Studies	4,342,626	10.40%
Fourth Swedish National Pension Fund	4,060,000	9.73%
Third Swedish National Pension Fund	1,692,330	4.05%
Avanza Pension	1,484,513	3.56%
Second Swedish National Pension Fund	1,255,012	3.01%
Unionen	1,123,273	2.69%
Carl Erik Norman	868,548	2.08%
Handelsbanken Fonder	480,023	1.15%
Total, 10 largest owners	**27,704,354**	**66.37%**
Other shareholders	**14,037,986**	**33.63%**
Total	**41,742,340**	**100.0%**

Financial calendar

Annual General Meeting	May 12, 2026
Interim Report Q2 2026	August 5, 2026
Interim Report Q3 2026	November 5, 2026
Year-end Report 2026	February 11, 2027

The financial reports are available on the Xspray Pharma website, www.xspraypharma.com.

Analysts monitoring the company

Filip Einarsson, Redeye AB

Share price performance



Financial performance

Unless otherwise indicated, the comments below pertain to the Group. The Group comprises the Parent Company, a dormant subsidiary and a US subsidiary. The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) and the Parent Company's statements have been prepared in accordance with RFR2.

Net sales
Net sales for the company amounted to SEK 0 thousand in the first quarter of 2026. Sales are expected to increase when the company launches its products in the US market. For further information on the pipeline, refer to pages 4–5.

Other operating income
Other operating income for the first quarter of 2026 amounted to SEK 557 thousand (1,922). Other operating income primarily consists of exchange rate gains arising in conjunction with payments abroad and translation of the currency accounts and license revenue.

Research and development costs
Total expenditures for research and development for the quarter amounted to SEK -4,143 thousand (-20,638), of which SEK -2,097 thousand (-4,894) was recognized as an expense in profit or loss and SEK -2,046 thousand (-15,744) was capitalized as development expenditure in the company's balance sheet. The decrease in development expenses is attributable to the conclusion of several clinical studies for product candidate Nilopki®, with the project thus becoming less cost-intensive. Research and development costs, however, remain attributable to the other product candidates such as XS008 axitinib and XS025 cabozantinib.

Administration and sales expenses
Administration and sales expenses totaled SEK -30,008 thousand (-36,031) in the first quarter. Of these, personnel costs amounted to SEK -12,161 thousand (-10,627). These costs consist largely of preparatory activities for Dasynoc® and Nilopki®.

Other operating expenses
Other operating expenses totaled SEK -121 thousand (-462) for the first quarter. Other operating expenses consist of exchange rate losses arising in conjunction with payments abroad and translations of the currency account.

Finance income
Finance income for the first quarter amounted to SEK 516 thousand (904). The item consists entirely of interest income from bank accounts.

Finance costs
Finance costs amounted to SEK -4,227 thousand (-3,760) for the first quarter. The increase year-on-year is due to interest expenses related to the short-term loan.

Loss for the period
Loss for the first quarter totaled SEK -35,362 thousand (-42,291). This corresponds to earnings per share before dilution of SEK -0.85 (-1.14).

Cash flow
Cash flow from operating activities amounted to SEK -30,676 thousand (-66,329) in the quarter, of which the effect from working capital comprised SEK 3,354 thousand (-25,140).

Cash flow from investing activities in the Group amounted to SEK -1,067 thousand (-14,701) for the first quarter. The item consists entirely of capitalized development expenditure, with the reduction attributable primarily to the Nilopki® project no longer being in a period of equally intensive research and development.

Investment in property, plant and equipment in the period amounted to SEK 0 thousand (0).

Cash flow from financing activities in the first quarter was SEK -1,379 thousand (-1,391), which is attributable primarily to amortization of lease liabilities. Total cash flow was SEK -33,122 thousand (-82,421).

Intangible assets
Development expenditures for the projects have been capitalized according to plan. Capitalized development expenditures for the quarter totaled SEK 2,046 thousand (15,744). The item is associated with the company's product candidates Dasynoc®, Nilopki®, XS008 axitinib and XS025 cabozantinib.

Financial position
During the quarter, the Board resolved to carry out a new issue of shares of approximately SEK 83 million, with preferential rights for the company's existing shareholders. The new share issue was also increased by an additional SEK 30 million through an over-allotment option. The company also has an existing loan of SEK 125 million, with the maturity set for February 2027.

The company's future capital requirements are impacted by several factors, including the timing of the launch and the market's uptake of the company's initial product candidates, Dasynoc® and Nilopki®, as well outcomes and costs attributable to ongoing and future drug studies. Depending on the development of these factors over the next year, the Group's coverage of cash and cash equivalents will fall below the liquidity needed to pursue operations for the coming 12 months.

In light of this, the Board of Directors is actively engaged in evaluating the company's financial requirements and position, with various financing alternatives continually being reviewed. The equity/assets ratio for the Group was 77.3 percent (78.7) at March 31, 2026.

Group structure
The Group structure comprises the Parent Company, Xspray Pharma AB (publ), corporate identity number 556649-3671, and its wholly owned subsidiaries Xspray Pharma Futurum AB, corporate identity number 559178-7642, and Xspray Pharma Inc. The two Swedish limited liability companies have their offices in Solna, Sweden, and the US subsidiary has its offices in Delaware. The address of the head office is Scheeles väg 2, SE-171 65 Solna, Sweden.

Parent Company
Operations were conducted primarily in the Parent Company, Xspray Pharma AB (publ). The Parent Company's cash and cash equivalents totaled SEK 117,062 thousand (124,601) and the equity/assets ratio was 79.8 percent (81.8) at March 31, 2026.

Employees
The number of employees in the organization decreased by two compared with the year-earlier period. The average number of employees in the Group totaled 24 (26).

Related-party transactions
The management of the Parent Company, the Boards of Directors of the Parent Company and subsidiary are defined as related parties.

Purchase of services from senior executives during the period pertain to consultant fees to M von Euler Consulting AB, owned by Mikael von Euler, who has been part of the company's executive management team since October 2025. The fees for the quarter thus totaled SEK -528 thousand (-309).

During the quarter, the company had costs that were invoiced onward from Flerie Invest, which is the company's largest owner. These costs amounted to SEK 1,050 thousand (0).

Financial statements

Consolidated income statement

	Q1		Full year
SEK thousand	**2026**	**2025**	**2025**
Net sales	-	-	-
Other operating income	557	1,922	6,432
Research and development expenses	-2,097	-4,894	-10,750
Administration and sales expenses	-30,008	-36,031	-151,103
Other operating expenses	-121	-462	-1,489
Operating loss	**-31,669**	**-39,465**	**-156,910**
Finance income	516	904	2,215
Finance costs	-4,227	-3,760	-16,851
Finance net	**-3,711**	**-2,856**	**-14,636**
Loss before income tax	**-35,380**	**-42,321**	**-171,546**
Tax	18	31	104
Loss for the period	**-35,362**	**-42,291**	**-171,443**
Earnings per share for the period before dilution, SEK	-0.85	-1.14	-4.46
Earnings per share for the period after dilution, SEK	-0.85	-1.14	-4.46
Average number of shares before dilution	41,742,340	37,138,491	38,453,876
Average number of shares after dilution	41,742,340	37,138,491	38,453,876

Consolidated statement of comprehensive income

	Q1		Full year
SEK thousand	**2026**	**2025**	**2025**
Loss for the period	**-35,362**	**-42,291**	**-171,443**
Annual translation differences in the translation of foreign operations	123	-219	-444
Total comprehensive income for the period	**-35,239**	**-42,510**	**-171,887**

Profit for the period and comprehensive income are attributable in their entirety to Parent Company shareholders.

Consolidated balance sheet

SEK thousand	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
ASSETS			
Non-current assets			
Intangible assets			
Capitalized development costs	514,236	494,670	512,190
Total intangible assets	**514,236**	**494,670**	**512,190**
Property, plant and equipment			
Machinery and installations	907	3,015	1,434
Right-of-use assets	25,197	30,803	26,598
Equipment	1,453	1,908	1,566
Fixed assets under construction and prepayments	41,389	41,389	41,389
Total Property, plant and equipment	**68,946**	**77,115**	**70,988**
Financial assets			
Financial investments	1	1	1
Other long-term receivables	3,288	3,198	3,271
Total financial assets	**3,289**	**3,199**	**3,272**
Total non-current assets	**586,472**	**574,984**	**586,450**
Current assets			
Inventories	22,926	30,006	22,296
Current receivables	3,174	3,758	3,842
Prepaid expenses and accured income	3,096	3,235	3,012
Cash and cash equivalents	120,721	125,725	153,745
Total current assets	**149,917**	**162,723**	**182,896**
TOTAL ASSETS	**736,388**	**737,708**	**769,346**

Consolidated balance sheet cont.

SEK thousand	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
EQUITY AND LIABILITIES			
Equity			
Share capital	41,742	37,138	41,742
Other contributed capital	1,573,990	1,425,079	1,574,042
Reserves	677	778	553
Retained earnings including profit/loss for the period	-1,047,052	-882,537	-1,011,689
Total equity attributable to the Parent Company's shareholders	**569,358**	**580,458**	**604,649**
Non–current liabilities			
Lease liabilities	20,387	25,781	21,718
Liabilities to credit institutions	-	-	121,316*
Total non-current liabilities	**20,387**	**25,781**	**143,034**
Current liabilities			
Short-term interest-bearing liabilities	122,105	96,000	-
Trade accounts payable	3,876	7,462	3,323
Lease liabilities	5,362	5,177	5,358
Other current liabilities	649	10,049	1,132
Accrued expenses and deferred income	14,651	12,780	11,850
Total current liabilities	**146,644**	**131,468**	**21,663**
TOTAL EQUITY AND LIABILITIES	**736,388**	**737,708**	**769,346**

*The company's loan financing of SEK 125,000 thousand was reclassified from non-current to current liabilities, since the loan matures on February 15, 2027.

Consolidated statement of changes in equity

SEK thousand	Share capital	Other contributed capital	Reserves	Retained earnings incl. profit/loss for the period	Total Equity
Opening balance as of January 1, 2025	**37,138**	**1,425,208**	**997**	**-840,247**	**623,097**
Loss of the period	-	-	-	-171,443	**-171,443**
Other comprehensive income for the period	-	-	-444	-	**-444**
Total comprehensive income for the period	-	-	**-444**	**-171,443**	**-171,887**
New share issue	4,604	156,531	-	-	**161,135**
Transaction costs	-	-7,656	-	-	**-7,656**
Warrant program	-	-41	-	-	**-41**
Closing balance as of December 31, 2025	**41,742**	**1,574,043**	**553**	**-1,011,689**	**604,649**
Opening balance as of January 1, 2026	**41,742**	**1,574,043**	**553**	**-1,011,689**	**604,649**
Loss of the period	-	-	-	-35,362	**-35,362**
Other comprehensive income for the period	-	-	123	-	**123**
Total comprehensive income for the period	-	-	**123**	**-35,362**	**-35,239**
New share issue	-	-	-	-	**-**
Transaction costs	-	-	-	-	**-**
Warrant program	-	-52	-	-	**-52**
Closing balance as of March 31, 2026	**41,742**	**1,573,990**	**677**	**-1,047,052**	**569,358**

Consolidated statement of cash flow

	Q1		Full year
SEK thousand	**2026**	**2025**	**2025**
Operating activities			
Operating loss	-31,669	-39,465	-156,910
Non-cash adjustments			
Depreciation	1,387	1,415	5,579
Interest received	3	-	2,215
Interest paid	-3,751	-3,139	-13,620
Cash flow from operating activities before changes in working capital	**-34,030**	**-41,189**	**-162,736**
Changes in working capital			
Change in inventory	-630	-9,671	-1,961
Change in operating receivables	1,119	271	-400
Change in operating liabilities	2,865	-15,740	-28,066
Cash flow from operating activities	**-30,676**	**-66,329**	**-193,163**
Investing activities			
Capitalized development costs	-1,067	-14,701	-29,186
Cash flow from investing activities	**-1,067**	**-14,701**	**-29,186**
Financing activities			
New share issue	-	-	161,134
Loan raised	-	-	120,000
Payment of loan	-	-	-100,000
Transaction costs	-	-129	-7,656
Payment of lease liability	-1,327	-1,262	-5,144
Repurchased warrants	-52	-	-41
Cash flow from financing activities	**-1,379**	**-1,391**	**168,293**
Cash flow for the period	**-33,122**	**-82,421**	**-54,056**
Cash and cash equivalents at the beginning of the period	153,745	208,236	208,236
Effect of exchange rate and value changes in cash and cash equivalents	98	-90	-435
Cash and cash equivalents at the end of the period	**120,721**	**125,725**	**153,746**

Parent Company income statement

	Q1		Full year
SEK thousand	**2026**	**2025**	**2025**
Net sales	-	-	-
Other operating income	557	1,922	6,432
Research and development expenses	-2,757	-5,447	-12,996
Administration and sales expenses	-30,150	-36,233	-151,918
Other operating expenses	-121	-462	-1,489
Operating loss	**-32,471**	**-40,219**	**-159,971**
Finance income	514	904	2,211
Finance costs	-4,227	-3,760	-16,851
Finance net	**-3,713**	**-2,856**	**-14,640**
Loss before Income tax	-36,184	-43,076	-174,611
Loss for the period	**-36,184**	**-43,076**	**-174,611**

Parent Company balance sheet

SEK thousand	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
ASSETS			
Non-current assets			
Intangible assets			
Capitalized development costs	504,677	488,399	503,500
Total intangible assets	**504,677**	**488,399**	**503,500**
Property, plant and equipment			
Machinery and installations	907	3,015	1,434
Equipment	1,453	1,908	1,566
Fixed assets under construction and prepayments	41,389	41,389	41,389
Total Property, plant and equipment	**43,749**	**46,313**	**44,390**
Financial assets			
Shares in subsidiaries	3,505	2,238	3,505
Financial investments	1	1	1
Other long-term receivables	2,999	2,999	2,999
Total financial assets	**6,505**	**5,237**	**6,505**
Total non-current assets	**554,931**	**539,949**	**554,395**
Current assets			
Inventories	**22,926**	**30,006**	**22,296**
Current receivables			
Other current receivables	3,409	4,013	4,077
Prepaid expenses and accured income	3,948	4,046	3,854
Total current receivables	**7,357**	**8,060**	**7,931**
Cash and bank	117,062	124,601	151,159
Total current assets	**147,345**	**162,667**	**181,385**
TOTAL ASSETS	**702,276**	**702,616**	**735,780**

Parent Company balance sheet cont.

SEK thousand	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	41,742	37,138	41,742
Statutory reserve	976	976	976
Development expenditure reserve	504,677	488,399	503,500
Total restricted equity	**547,395**	**526,514**	**546,219**
Non-restricted equity			
Other contributed capital	1,576,990	1,428,079	1,577,042
Accumulated earnings	-1,527,558	-1,336,670	-1,351,770
Profit/loss for the period	-36,184	-43,076	-174,611
Total non-restricted equity	**13,247**	**48,334**	**50,660**
Total equity	**560,643**	**574,848**	**596,879**
Non–current liabilities			
Liabilities to credit institutions	-	-	121,316 *
Total non-current liabilities	**-**	**-**	**121,316**
Current liabilities			
Short-term interest-bearing liabilities	122,105	96,000	-
Trade accounts payable	3,857	8,939	3,310
Other current liabilities	649	10,049	2,435
Accrued expenses and deferred income	15,021	12,780	11,841
Total current liabilities	**141,633**	**127,768**	**17,585**
TOTAL EQUITY AND LIABILITIES	**702,276**	**702,616**	**735,780**

*The company's loan financing of SEK 125,000 thousand was reclassified from non-current to current liabilities, since the loan matures on February 15, 2027.

Parent Company statement of cash flow

	Q1		Full year
SEK thousand	**2026**	**2025**	**2025**
Operating activities			
Operating loss	**-32,471**	**-40,219**	**-159,971**
Non-cash adjustments			
Depreciation	640	667	2,591
Interest received	1	-	2,211
Interest paid	-3,438	-2,760	-12,201
Cash flow from operating activities before changes in working capital	**-35,268**	**-42,312**	**-167,370**
Changes in working capital			
Changes in inventory	-629	-9,671	-1,962
Change in operating receivables	1,045	396	-355
Change in operating liabilities	1,942	-15,472	-27,988
Cash flow from operating activities	**-32,910**	**-67,059**	**-197,675**
Investing activities			
Purchase of intangible assets	-1,177	-14,918	-30,019
Group contributions	-	-	-1,267
Cash flow from investing activities	**-1,177**	**-14,918**	**-31,286**
Financing activities			
New share issue	-	-	161,134
Transaction costs	-	-129	-7,656
Loan raised	-	-	120,000
Payment of loan	-	-	-100,000
Repurchased warrants	-52	-	-41
Cash flow from financing activities	**-52**	**-129**	**173,437**
Cash flow for the period	**-34,139**	**-82,106**	**-55,524**
Cash and cash equivalents at the beginning of the period	151,159	206,682	206,682
Effect of exchange rate and value changes in cash and cash equivalents	42	25	-
Cash and cash equivalents at the end of the period	**117,062**	**124,601**	**151,159**

Notes

Note 1. Accounting and measurement policies

The interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) and with the applicable provisions in the Swedish Annual Accounts Act. The interim report for the Parent Company has been prepared in accordance with Chapter 9, "Interim Reports", of the Annual Accounts Act. For the Parent Company and the Group, the same accounting policies and bases for calculation as in the Annual Report for 2025 have been applied. Comparison figures are presented in parentheses and pertain to the same period in 2025.

Note 2. Key estimates and assessments

Preparing the financial statements in accordance with IFRS requires management to make assessments and estimates, and to make assumptions that impact the application of the accounting policies and the recognized amounts of assets, liabilities, revenue and expenses. The real outcome may deviate from these estimates and assumptions. The estimates and assumptions are evaluated regularly. Changes to estimates are recognized in the period the changes are made.

The source of uncertainty in estimations that entail a significant risk for the need to significantly adjust the value of assets or liabilities during the coming financial year is the carrying amount of "Capitalized development expenditure". Determining whether the requirements for capitalization of development expenditure have been met requires both initial and routine assessments. The capitalized expenditures are regularly tested as to whether they could be exposed to a decrease in value. The company holds capitalized intangible assets that have not yet been completed and are impairment tested either yearly or as soon as there is an indication of a potential decrease in value. Impairment tests involve estimates of future cash flows attributable to the asset or the cash-generating unit to which the asset relates when it is complete. These estimates and judgments involve expectations primarily regarding the selling price of products, market penetration, remaining development, sales and marketing expenses, and the likelihood that the product passes through the remaining development phases. The assumptions involve industry- and market-specific data produced by corporate management and reviewed by the Board of Directors.

Material risks and uncertainties

Xspray Pharma's operation is associated with both industry-related and company-specific risks. The company develops product candidates, and there will always be regulatory, market-related and financial risks in the operation. The CRL for Dasynoc, which concerns deficiencies at the contract manufacturer, falls within the regulatory and supplier-related risks that have already been described in the company's earlier prospectus and in the Annual Report. The CRL was addressed through the re-submitted application that the FDA accepted, and the company believes that the supplier-related issues will not impact the schedule for approval or launch. In all essentials, the risks and uncertainties are the same as those reported in the company's 2025 Annual Report.

Financing risk and going concern

The company's future capital requirements are impacted by several factors, including the timing of the launch and the market's uptake of the company's initial product candidates, Dasynoc® and Nilopki®, as well outcomes and costs attributable to ongoing and future drug studies. Depending on the development of these factors over the next year, the Group's coverage of cash and cash equivalents will fall below the liquidity needed to pursue operations for the coming 12 months.

In light of this, the Board is monitoring the situation and is evaluating different financing options including timing and scope for raising capital that can be beneficial to the company. If the financing secured is not sufficient, it would suggest material uncertainties that could lead to significant doubt regarding the company's capacity to continue its operations. In accordance with the policy by the Board of Directors, the Group must maintain a strong financial position, which will help the company retain investor and market confidence. It also creates a foundation for further development of company operations, with continued long-term support for its goal of securing returns for the company's owners. Until the company has achieved long-term, sustainable profitability, its policy is to maintain a reasonable level of debt and a high level of equity.

Definitions of key performance indicators

Earnings per share are calculated as earnings for the period divided by the average number of shares during the period. The equity/assets ratio is equity as a percentage of the balance sheet total. Research and development costs as a percentage of operating expenses equate to expensed research and development expenses divided by operating expenses. Total operating expenses consist of operating profit less net sales and other operating income. The carrying amount of receivables, cash and cash equivalents, trade payables and other liabilities constitute a reasonable approximation of fair value.

Assurance from the Board

The Board of Directors and the CEO declare that this quarterly report provides a true and fair overview of the Group's and Parent Company's business operations, financial position and performance and describes principal risks and uncertainties faced by the company.

Solna, April 28, 2026

Anders Ekblom
Chairman

Anders Bladh
Board member

Robert Molander
Board member

Markus Haeberlein
Board member

Anne Prener
Board member

Christine Lind
Board member

Carl-Johan Spak
Board member

Per Andersson
CEO

This report has not been reviewed by the company's auditors.

Glossary

505(b)(2) NDA	Application for drug approval in the US for an improved version of an approved drug.
Amorphous	An amorphous structure is a chemical term that describes substances whose molecules lack an ordered structure.
Bioequivalence	Term used to describe whether two different drugs are processed in a similar manner by the body and are thereby expected to have a similar and equivalent medicinal effect. If it can be confirmed that two drugs being compared are bioequivalent, they can be expected to have the same efficacy and safety.
Bioavailability	(Biological availability), a concept in pharmacology that shows how large a portion of the drug reaches the blood.
FDA	Food and Drug Administration. The US food and drug authority responsible for foodstuffs, nutritional supplements, drugs, cosmetics, medical equipment, radiation-emitting equipment and blood products.
Crystalline	A crystalline structure is a chemical term that describes an ordered structure among the molecules of the substance.
PDUFA date	A target date that the US Food and Drug Administration has set for making a decision on a new drug (Prescription Drug User Fee Act).
Pilot study	An initial study conducted on a smaller scale than a pivotal study. A pilot study can be used both to check whether the arrangement of the study is a functional one, and to collect data that can later be used as control values in the full study.
Pivotal study	A study whose results can be used in an application for approval from a medical products authority.
Protein kinase inhibitor (PKI)	Drugs that block protein kinases. Protein kinase inhibitors work by blocking activity in enzymes that push the development and growth of cancer cells.
Proton-pump inhibitor (PPI)	A proton-pump inhibitor is a group of drugs whose primary effect is a clear and long-lasting decrease in the production of gastric acid.
Tyrosine kinase inhibitor (TKI)	Tyrosine kinase inhibitors are a subgroup of protein kinase inhibitors. This cancer drug group blocks growth-stimulating signals within the cells.
Variability	The scope of the distribution in the form of low and high values around the average value as regards the body's uptake of drugs.

For more information,
please contact:

Jacob Nyberg, IR
Phone: +46 (0) 8 730 37 00
E-mail: ir@xspray.com
www.xspraypharma.com